Home Pharma China Web Edition Pharma China Archives Online Databases Subscription/Order/Info Event Calendar China Pharma Providers About Us
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Featured News
Editorials
Commentaries
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor´s Picks
 
 
 
MNCs Play Defensive despite China's Renewed Access and Trade Pledges
Chief Editor James Shen offers his monthly review of the Chinese healthcare sector with this issue's emphasis on recent trends in international trade relations and scaled... (11/30/2017)
   
Biopharmaceutical Manufacturing Growing Rapidly in China (12/4/2017)
US Healthcare Could Be the Booster Shot That "Healthy China" Needs (12/4/2017)
MNCs Play Defensive despite China's Renewed Access and Trade Pledges (11/30/2017)
Expect More US Corruption Probes Involving Firms with Links to China (11/23/2017)
Investors Place Bet on Chinese Drugmakers (11/23/2017)
China's FDA Reform Will Encourage Life Science Innovation (11/23/2017)
Guangzhou Pharma Reveals Grand Plan (11/22/2017)
Update on Antitrust Legislative Development in China (11/15/2017)
Competition Impact Review to Be Required for All New Chinese Regulations (11/15/2017)
Ongoing Healthcare Reform in China (11/14/2017)
U.S. Employs Rarely Used Tool to Probe China IP Practices (11/14/2017)
Time for MNCs to Stay Sober as China Unleashes Enticing Drug Regulatory Reform (11/10/2017)
EddingPharm Spinoff Strives to Bring Potential Oncology Blockbusters to China (11/7/2017)
China's Healthcare Crisis: Both Rich and Poor Travel Abroad (11/1/2017)
Three Trends in Pharma Globalization (10/31/2017)
Fujian Introduces New Policy to Differen...  (12/15/2017)
Recent Executive Moves  (12/15/2017)
CFDA Approves Expanded Indication of Eis...  (12/14/2017)
Ipsen, Zhejiang MedTech Enter Strategic ...  (12/14/2017)
CFDA Accepts Innovent Biologics' NDA for...  (12/14/2017)
CFDA Solicits Comments on Two Clinical G...  (12/13/2017)
Shanghai Establishes Regional Ethics Com...  (12/13/2017)
Bayer Announces CFDA Approval of Stivarg...  (12/13/2017)
Galderma to Spin Off Drug Business in Ch...  (12/13/2017)
Upcoming Event: 8th Annual Generic Inter...  (12/12/2017) (free)
CFDI to Initiate Clinical Data Inspectio...  (12/12/2017)
Boai NKY Pharma to Buy BioVision for $29...  (12/11/2017)
CFDA Approves Genscript's Clinical Trial...  (12/11/2017)
BGI Genomics to Set Up JV with TCM Playe...  (12/11/2017) (free)
Upcoming Event: Wellness China 2018  (12/11/2017) (free)
Global Contract Pharmaceutical Manufacturing Market to R...
White House Task Force Echoes Pharma Proposals
Pharma Industry Reputation Rebounds Somewhat in 2016
Fresenius Steps Up Pharma M&A with Akorn, Merck KGaA...
Global Pharmerging Market to Grow at a CAGR of 12.88% in...
NH Reports on Chinese OTC Sleep Aids Market in MAT Q3/2017
China to Slash Import Duties to Boost Domestic Consumption and ...
Chinese CRO Market Expected to Rise Fast by 2022
McKinsey: Chinese Healthcare Market to Reach $1 Trillion by 202...
SMEI: Chinese Drug Sales Growth Expected to Fall Further in 201...
CFDA Approves Expanded Indication of Eisai's Aricept to Seve...
Ipsen, Zhejiang MedTech Enter Strategic Alliance for Tanakan...
Shanghai Establishes Regional Ethics Committee for Clinical ...
Bayer Announces CFDA Approval of Stivarga as Second Line Tre...
Galderma to Spin Off Drug Business in China
CFDA Solicits Comments on Two Clinical Guidelines for Sp...
CFDI to Initiate Clinical Data Inspection of Five Drug P...
CFDA Seeks Feedbacks on Rules for Food and Drug Law Enfo...
CFDA Issues New Announcement (2017#149) for Clinical Dat...
CFDA Solicits Comments on Provisions for Common Evaluati...
Shanghai Fines NT Pharma for Use of Financial Incentives to ...
Shanghai Fines BMS for Paying Conference Expenditures of Key...
China Issues New Measure to Ensure Fair Competition
China Stiffens Penalty on Parties Offering Bribes with Amend...
Shanghai Fines Novo Nordisk CNY 2.6 Mln for Distributor Lice...
China to Restrict Production of API Producers in 28 Citi...
Asymchem Labs Announces 2nd TGA Inspection of Its Jilin ...
French Authority Warns Chongqing API Producer over GMP V...
Another Chinese API Producer in Data Integrity Mudpool a...
U.S. FDA Warns Chinese API Producer for Absence of Writt...
CFDA Accepts Innovent Biologics' NDA for PD-1 Candidate ...
CFDA Approves Genscript's Clinical Trial Application for...
BeyondSpring Initiates Global Phase 2/3 Trial of Plinabu...
Eisai's Resubmitted NDA for Anticancer Agent Halaven Acc...
China Approves Use of Recombinant Interferon against Avi...
Fujian Introduces New Policy to Differentiate Drug Produ...
Universities Form Canada-China Alliance for Precision Me...
China Introduces New Plan to Control Spread of Viral Hep...
China Witnesses Growing Incidence of Mental Illnesses Na...
China Embraces AI for Diagnosis of Lung Cancer
Recent Executive Moves
Recent Executive Moves
Recent Executive Moves
Recent Executive Moves
Recent Official and Executive Moves
Upcoming Event: 8th Annual Generic International Asia Su...
Upcoming Event: Wellness China 2018
Upcoming Event: Asia Clinical Trials Innovation Summit 2...
Upcoming Event: Phar-East 2018
Upcoming Event: Pharma Biotech Congress 2018
Pharma China is the most influential English media and source of business intelligence covering the Chinese pharmaceutical and biopharmaceutical sector...
WiCON has been helping international healthcare companies succeed in China and other Asian markets since 1991. We advise our clients on every stage of their China and Asian business. We worked with clients in many regions of the world...
  WiCON Officially Publishes Chi...
  WiCON Officially Publishes Chi...
  WiCON and PharmaGuys Launch Ph...
  WiCON Officially Publishes Chi...
  WiCON Officially Publishes Its...
© Wicon International Group  Support by: www.heightow.com Site map | Contact Us | Links